CONDUENT

Drug Monograph

Drug/Drug Class:	**Levorphanol Tartrate Tablet / Short Acting Single Agent Opioids**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Levorphanol is now available in a 3 mg oral tablet. It is also available in a 2 mg tablet.
Manufacturer:	Distributed by: Sentynl Therapeutics, Inc., Solana Beach, CA 92075.
Indications:	Levorphanol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Costs:	$66.75 per tablet of levorphanol 3 mg. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current short acting single agent opioids clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Preferred ☒ Appropriate Indications ☐ No PA Required

Prepared by: Carrie Gatzke PharmD
Date: March 23, 2019

© 2019 Conduent Business Services, LLC All Rights Reserved.